Literature DB >> 29353400

A STARD-compliant prediction model for diagnosing thrombotic microangiopathies.

Pietro Manuel Ferraro1, Gianmarco Lombardi2, Alessandro Naticchia2, Antonio Sturniolo2, Cecilia Zuppi3, Valerio De Stefano4, Patrizia Bonelli5, Ruggero Buonocore5, Gianfranco Cervellin6, Giuseppe Lippi7, Giovanni Gambaro2.   

Abstract

Aim of the study was the definition of a predictive model for the initial diagnosis of thrombotic microangiopathies (TMA). We retrospectively collected data on all adult patients admitted to the Gemelli Hospital from 2010 to 2014. ICD-9 codes from primary diagnoses were used for TMA diagnosis. Demographic and laboratory characteristics on admission of patients with TMA were then compared with a random sample of 500 patients with other diagnoses. The prediction model was externally validated in a cohort from another hospital. Overall, 23 of 187,183 patients admitted during the study period received a primary diagnosis of TMA. LDH (OR 1.26, 95% CI 1.05, 1.63) and platelets (OR 0.96, 95% CI 0.94, 0.98) were the only independent predictors of TMA. The AUROC of the final model including only LDH and platelets was 0.96 (95% CI 0.91, 1.00). The Hosmer-Lemeshow (HL) test (p = 0.54) suggested good calibration. Our model also confirmed good discriminatory power (AUROC 0.72 95% CI 0.60, 0.84) and calibration (HL test p = 0.52) in the validation sample. We present a simple prediction model for use in diagnosing TMA in hospitalized patients. The model performs well and can help clinicians to identify patients at high risk of TMA.

Entities:  

Keywords:  External validation; Multivariate analysis; Predictive model; Thrombotic microangiopathies

Mesh:

Substances:

Year:  2018        PMID: 29353400     DOI: 10.1007/s40620-018-0468-4

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  18 in total

Review 1.  Clinical practice. Thrombotic thrombocytopenic purpura.

Authors:  James N George
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

2.  Thrombotic thrombocytopenic purpura: 2008 update.

Authors:  Mark A Crowther; James N George
Journal:  Cleve Clin J Med       Date:  2008-05       Impact factor: 2.321

Review 3.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 4.  Thrombotic thrombocytopenic purpura--then and now.

Authors:  Miriam Galbusera; Marina Noris; Giuseppe Remuzzi
Journal:  Semin Thromb Hemost       Date:  2006-03       Impact factor: 4.180

5.  Systemic infections mimicking thrombotic thrombocytopenic purpura.

Authors:  Kristina K Booth; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Am J Hematol       Date:  2011-09       Impact factor: 10.047

Review 6.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

Review 7.  Escherichia coli O157:H7.

Authors:  P S Mead; P M Griffin
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

Review 8.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

9.  Consequences of hemolytic uremic syndrome among hemodialysis patients.

Authors:  Steven M Brunelli; Ami Claxton; Sunil Mehta; Emmanuel A Anum
Journal:  J Nephrol       Date:  2014-12-10       Impact factor: 3.902

10.  Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.

Authors:  Johan Vande Walle; Yahsou Delmas; Gianluigi Ardissino; Jimmy Wang; John F Kincaid; Herman Haller
Journal:  J Nephrol       Date:  2016-03-19       Impact factor: 3.902

View more
  1 in total

1.  Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report.

Authors:  Luca Calvaruso; Alessandro Naticchia; Pietro Manuel Ferraro; Gisella Vischini; Stefano Costanzi
Journal:  Case Rep Nephrol       Date:  2019-07-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.